{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:33:16Z","timestamp":1793496796144,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["742432"],"award-info":[{"award-number":["742432"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Eve Appeal"},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2017-00932, 2012-02961"],"award-info":[{"award-number":["2017-00932, 2012-02961"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN 2016\/696"],"award-info":[{"award-number":["CAN 2016\/696"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007232","name":"Radiumhemmets Forskningsfonder","doi-asserted-by":"publisher","award":["154143, 184033"],"award-info":[{"award-number":["154143, 184033"]}],"id":[{"id":"10.13039\/501100007232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","award":["IS-BRC-1215-20007"],"award-info":[{"award-number":["IS-BRC-1215-20007"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/P014070\/1"],"award-info":[{"award-number":["MR\/P014070\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p> Breast cancer is a leading cause of death in premenopausal women. Progesterone drives expansion of luminal progenitor cells, leading to the development of poor-prognostic breast cancers. However, it is not known if antagonising progesterone can prevent breast cancers in humans. We suggest that targeting progesterone signalling could be a means of reducing features which are known to promote breast cancer formation.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In healthy premenopausal women with and without a BRCA mutation we studied (i) estrogen and progesterone levels in saliva over an entire menstrual cycle (<jats:italic>n<\/jats:italic> =\u200920); (ii) cancer-free normal breast-tissue from a control population who had no family or personal history of breast cancer and equivalently from <jats:italic>BRCA1\/2<\/jats:italic> mutation carriers (<jats:italic>n<\/jats:italic> =\u200928); triple negative breast cancer (TNBC) biopsies and healthy breast tissue taken from sites surrounding the TNBC in the same individuals (<jats:italic>n<\/jats:italic> =\u200914); and biopsies of ER+ve\/PR+ve stage T1\u2013T2 cancers and healthy breast tissue taken from sites surrounding the cancer in the same individuals (<jats:italic>n<\/jats:italic> =\u200931); and (iii) DNA methylation and DNA mutations in normal breast tissue (before and after treatment) from clinical trials that assessed the potential preventative effects of vitamins and antiprogestins (mifepristone and ulipristal acetate; <jats:italic>n<\/jats:italic> =\u200944).\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Daily levels of progesterone were higher throughout the menstrual cycle of <jats:italic>BRCA1\/2<\/jats:italic> mutation carriers, raising the prospect of targeting progesterone signalling as a means of cancer risk reduction in this population. Furthermore, breast field cancerization DNA methylation signatures reflective of (i) the mitotic age of normal breast epithelium and (ii) the proportion of luminal progenitor cells were increased in breast cancers, indicating that luminal progenitor cells with elevated replicative age are more prone to malignant transformation. The progesterone receptor antagonist mifepristone reduced both the mitotic age and the proportion of luminal progenitor cells in normal breast tissue of all control women and in 64% of <jats:italic>BRCA1\/2<\/jats:italic> mutation carriers. These findings were validated by an alternate progesterone receptor antagonist, ulipristal acetate, which yielded similar results. Importantly, mifepristone reduced both the <jats:italic>TP53<\/jats:italic> mutation frequency as well as the number of <jats:italic>TP53<\/jats:italic> mutations in mitotic-age-responders.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These data support the potential usage of antiprogestins for primary prevention of poor-prognostic breast cancers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Clinical trial 1 <jats:italic>Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control \u2013 a randomized controlled trial<\/jats:italic>, clinicaltrialsregister.eu, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2009-009014-40\/results\">2009-009014-40<\/jats:ext-link>; registered on 20 July 2009.<\/jats:p>\n                <jats:p>Clinical trial 2 <jats:italic>The effect of a progesterone receptor modulator on breast tissue in women with BRCA1 and 2 mutations<\/jats:italic>, clinicaltrials.gov, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01898312\">NCT01898312<\/jats:ext-link>; registered on 07 May 2013.<\/jats:p>\n                <jats:p>Clinical trial 3 <jats:italic>A pilot prevention study of the effects of the anti- progestin Ulipristal Acetate (UA) on surrogate markers of breast cancer risk<\/jats:italic>,\u00a0clinicaltrialsregister.eu, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-001587-19\/GB\">2015-001587-19<\/jats:ext-link>; registered on\u00a015 July 2015.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13073-022-01063-5","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T01:02:46Z","timestamp":1655254966000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women"],"prefix":"10.1186","volume":"14","author":[{"given":"Thomas E.","family":"Bartlett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iona","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Haran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Reisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiriaki","family":"Papaikonomou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1572-498X","authenticated-orcid":false,"given":"Chiara","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Pashayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno M.","family":"Sim\u00f5es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Gareth","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talayeh S.","family":"Ghezelayagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakthivignesh","family":"Ponandai-Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nageswara R.","family":"Boggavarapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran G.","family":"Lalitkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha J.","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Ana","family":"Risques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelique Fl\u00f6ter","family":"R\u00e5destad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Dubeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Gemzell-Danielsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7778-8380","authenticated-orcid":false,"given":"Martin","family":"Widschwendter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,15]]},"reference":[{"issue":"1","key":"1063_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ccr.2007.12.003","volume":"13","author":"Y Husemann","year":"2008","unstructured":"Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, et al. Systemic spread is an early step in breast cancer. Cancer Cell. 2008;13(1):58\u201368.","journal-title":"Cancer Cell"},{"issue":"7634","key":"1063_CR2","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature20785","volume":"540","author":"H Hosseini","year":"2016","unstructured":"Hosseini H, Obradovic MMS, Hoffmann M, Harper KL, Sosa MS, Werner-Klein M, et al. Early dissemination seeds metastasis in breast cancer. Nature. 2016;540(7634):552\u20138.","journal-title":"Nature"},{"issue":"10","key":"1063_CR3","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/ncponc0319","volume":"2","author":"MB Sporn","year":"2005","unstructured":"Sporn MB, Liby KT. Cancer chemoprevention: scientific promise, clinical uncertainty. Nat Clin Pract Oncol. 2005;2(10):518\u201325.","journal-title":"Nat Clin Pract Oncol"},{"issue":"1","key":"1063_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrc702","volume":"2","author":"A Schatzkin","year":"2002","unstructured":"Schatzkin A, Gail M. The promise and peril of surrogate end points in cancer research. Nat Rev Cancer. 2002;2(1):19\u201327.","journal-title":"Nat Rev Cancer"},{"issue":"10074","key":"1063_CR5","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","volume":"389","author":"N Harbeck","year":"2017","unstructured":"Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389(10074):1134\u201350.","journal-title":"Lancet"},{"key":"1063_CR6","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41571-020-0388-9","volume":"17","author":"N Pashayan","year":"2020","unstructured":"Pashayan N, Antoniou AC, Ivanus U, Esserman LJ, Easton DF, French D, et al. Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nat Rev Clin Oncol. 2020;17:687\u2013705.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"1063_CR7","doi-asserted-by":"publisher","first-page":"djw302","DOI":"10.1093\/jnci\/djw302","volume":"109","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, McGuffog L, Barrowdale D, Lee A, Soucy P, Dennis J, et al. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 2017;109(7):djw302.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1063_CR8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","volume":"21","author":"N Mavaddat","year":"2012","unstructured":"Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1\/2 (CIMBA). Cancer Epidemiol Biomark Prev. 2012;21(1):134\u201347.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"8","key":"1063_CR9","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/jnci\/djy106","volume":"110","author":"H Shimelis","year":"2018","unstructured":"Shimelis H, LaDuca H, Hu C, Hart SN, Na J, Thomas A, et al. Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing. J Natl Cancer Inst. 2018;110(8):855\u201362.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"1063_CR10","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674\u201390.","journal-title":"Nat Rev Clin Oncol"},{"issue":"14","key":"1063_CR11","doi-asserted-by":"publisher","first-page":"e100852","DOI":"10.15252\/embj.2018100852","volume":"38","author":"P Tharmapalan","year":"2019","unstructured":"Tharmapalan P, Mahendralingam M, Berman HK, Khokha R. Mammary stem cells and progenitors: targeting the roots of breast cancer for prevention. EMBO J. 2019;38(14):e100852.","journal-title":"EMBO J"},{"issue":"20","key":"1063_CR12","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938\u201348.","journal-title":"N Engl J Med"},{"issue":"7403","key":"1063_CR13","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nature10933","volume":"486","author":"SP Shah","year":"2012","unstructured":"Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395\u20139.","journal-title":"Nature"},{"issue":"6178","key":"1063_CR14","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1126\/science.1252230","volume":"343","author":"AR Venkitaraman","year":"2014","unstructured":"Venkitaraman AR. Cancer suppression by the chromosome custodians, BRCA1 and BRCA2. Science. 2014;343(6178):1470\u20135.","journal-title":"Science"},{"issue":"2","key":"1063_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10689-011-9506-2","volume":"11","author":"A Moran","year":"2012","unstructured":"Moran A, O'Hara C, Khan S, Shack L, Woodward E, Maher ER, et al. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Familial Cancer. 2012;11(2):235\u201342.","journal-title":"Familial Cancer"},{"issue":"3","key":"1063_CR16","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3390\/cancers12030547","volume":"12","author":"M Widschwendter","year":"2020","unstructured":"Widschwendter M, Dubeau L. Non-surgical cancer risk reduction in BRCA1 mutation carriers: disabling the remote control. Cancers (Basel). 2020;12(3):547.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1063_CR17","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.cub.2005.01.052","volume":"15","author":"R Chodankar","year":"2005","unstructured":"Chodankar R, Kwang S, Sangiorgi F, Hong H, Yen HY, Deng C, et al. Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells. Curr Biol. 2005;15(6):561\u20135.","journal-title":"Curr Biol"},{"issue":"6","key":"1063_CR18","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/labinvest.2012.58","volume":"92","author":"HY Yen","year":"2012","unstructured":"Yen HY, Gabet Y, Liu Y, Martin A, Wu NL, Pike MC, et al. Alterations in Brca1 expression in mouse ovarian granulosa cells have short-term and long-term consequences on estrogen-responsive organs. Lab Investig. 2012;92(6):802\u201311.","journal-title":"Lab Investig"},{"issue":"1","key":"1063_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1158\/0008-5472.CAN-09-3232","volume":"70","author":"H Hong","year":"2010","unstructured":"Hong H, Yen HY, Brockmeyer A, Liu Y, Chodankar R, Pike MC, et al. Changes in the mouse estrus cycle in response to BRCA1 inactivation suggest a potential link between risk factors for familial and sporadic ovarian cancer. Cancer Res. 2010;70(1):221\u20138.","journal-title":"Cancer Res"},{"issue":"12","key":"1063_CR20","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/S1470-2045(13)70448-0","volume":"14","author":"M Widschwendter","year":"2013","unstructured":"Widschwendter M, Rosenthal AN, Philpott S, Rizzuto I, Fraser L, Hayward J, et al. The sex hormone system in carriers of BRCA1\/2 mutations: a case-control study. Lancet Oncol. 2013;14(12):1226\u201332.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1063_CR21","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S1470-2045(19)30340-7","volume":"20","author":"NR Nene","year":"2019","unstructured":"Nene NR, Reisel D, Leimbach A, Franchi D, Jones A, Evans I, et al. Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study. Lancet Oncol. 2019;20(8):1171\u201382.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1063_CR22","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/j.ebiom.2015.08.037","volume":"2","author":"M Widschwendter","year":"2015","unstructured":"Widschwendter M, Burnell M, Fraser L, Rosenthal AN, Philpott S, Reisel D, et al. Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-kappaB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers. EBioMedicine. 2015;2(10):1331\u20139.","journal-title":"EBioMedicine"},{"issue":"7320","key":"1063_CR23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nature09387","volume":"468","author":"D Schramek","year":"2010","unstructured":"Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 2010;468(7320):98\u2013102.","journal-title":"Nature"},{"issue":"7299","key":"1063_CR24","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nature09091","volume":"465","author":"PA Joshi","year":"2010","unstructured":"Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, et al. Progesterone induces adult mammary stem cell expansion. Nature. 2010;465(7299):803\u20137.","journal-title":"Nature"},{"issue":"7320","key":"1063_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nature09495","volume":"468","author":"E Gonzalez-Suarez","year":"2010","unstructured":"Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature. 2010;468(7320):103\u20137.","journal-title":"Nature"},{"issue":"182","key":"1063_CR26","doi-asserted-by":"publisher","first-page":"182ra155","DOI":"10.1126\/scitranslmed.3005654","volume":"5","author":"T Tanos","year":"2013","unstructured":"Tanos T, Sflomos G, Echeverria PC, Ayyanan A, Gutierrez M, Delaloye JF, et al. Progesterone\/RANKL is a major regulatory axis in the human breast. Sci Transl Med. 2013;5(182):182ra155.","journal-title":"Sci Transl Med"},{"issue":"8","key":"1063_CR27","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/nm.4118","volume":"22","author":"E Nolan","year":"2016","unstructured":"Nolan E, Vaillant F, Branstetter D, Pal B, Giner G, Whitehead L, et al. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat Med. 2016;22(8):933\u20139.","journal-title":"Nat Med"},{"issue":"4","key":"1063_CR28","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1001\/jama.2020.9482","volume":"324","author":"RT Chlebowski","year":"2020","unstructured":"Chlebowski RT, Anderson GL, Aragaki AK, Manson JE, Stefanick ML, Pan K, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women\u2019s health initiative randomized clinical trials. JAMA. 2020;324(4):369\u201380.","journal-title":"JAMA"},{"issue":"5804","key":"1063_CR29","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1126\/science.1130471","volume":"314","author":"AJ Poole","year":"2006","unstructured":"Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science. 2006;314(5804):1467\u201370.","journal-title":"Science"},{"issue":"11","key":"1063_CR30","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1093\/humrep\/dey296","volume":"33","author":"K Papaikonomou","year":"2018","unstructured":"Papaikonomou K, Kopp Kallner H, Soderdahl F, Gemzell-Danielsson K. Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial. Hum Reprod. 2018;33(11):2002\u20139.","journal-title":"Hum Reprod"},{"issue":"1","key":"1063_CR31","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/nprot.2014.006","volume":"9","author":"S Picelli","year":"2014","unstructured":"Picelli S, Faridani OR, Bjorklund AK, Winberg G, Sagasser S, Sandberg R. Full-length RNA-seq from single cells using Smart-seq2. Nat Protoc. 2014;9(1):171\u201381.","journal-title":"Nat Protoc"},{"issue":"11","key":"1063_CR32","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1038\/nprot.2014.170","volume":"9","author":"SR Kennedy","year":"2014","unstructured":"Kennedy SR, Schmitt MW, Fox EJ, Kohrn BF, Salk JJ, Ahn EH, et al. Detecting ultralow-frequency mutations by Duplex Sequencing. Nat Protoc. 2014;9(11):2586\u2013606.","journal-title":"Nat Protoc"},{"issue":"36","key":"1063_CR33","doi-asserted-by":"publisher","first-page":"14508","DOI":"10.1073\/pnas.1208715109","volume":"109","author":"MW Schmitt","year":"2012","unstructured":"Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB, Loeb LA. Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci U S A. 2012;109(36):14508\u201313.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1063_CR34","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nmeth.3351","volume":"12","author":"MW Schmitt","year":"2015","unstructured":"Schmitt MW, Fox EJ, Prindle MJ, Reid-Bayliss KS, True LD, Radich JP, et al. Sequencing small genomic targets with high efficiency and extreme accuracy. Nat Methods. 2015;12(5):423\u20135.","journal-title":"Nat Methods"},{"issue":"7418","key":"1063_CR35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas N","year":"2012","unstructured":"Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61\u201370.","journal-title":"Nature"},{"issue":"1","key":"1063_CR36","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s13059-016-1064-3","volume":"17","author":"Z Yang","year":"2016","unstructured":"Yang Z, Wong A, Kuh D, Paul DS, Rakyan VK, Leslie RD, et al. Correlation of an epigenetic mitotic clock with cancer risk. Genome Biol. 2016;17(1):205.","journal-title":"Genome Biol"},{"issue":"1","key":"1063_CR37","doi-asserted-by":"publisher","first-page":"23702","DOI":"10.1038\/s41598-021-03161-7","volume":"11","author":"TE Bartlett","year":"2021","unstructured":"Bartlett TE, Jia P, Chandna S, Roy S. Inference of tissue relative proportions of the breast epithelial cell types luminal progenitor, basal, and luminal mature. Sci Rep. 2021;11(1):23702.","journal-title":"Sci Rep"},{"issue":"2","key":"1063_CR38","first-page":"85","volume":"9","author":"C Dielen","year":"2017","unstructured":"Dielen C, Fiers T, Somers S, Deschepper E, Gerris J. Correlation between saliva and serum concentrations of estradiol in women undergoing ovarian hyperstimulation with gonadotropins for IVF\/ICSI. Facts Views Vis Obgyn. 2017;9(2):85\u201391.","journal-title":"Facts Views Vis Obgyn"},{"issue":"6","key":"1063_CR39","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrc3518","volume":"13","author":"C Brisken","year":"2013","unstructured":"Brisken C. Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat Rev Cancer. 2013;13(6):385\u201396.","journal-title":"Nat Rev Cancer"},{"issue":"6217","key":"1063_CR40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.1260825","volume":"347","author":"C Tomasetti","year":"2015","unstructured":"Tomasetti C, Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science. 2015;347(6217):78\u201381.","journal-title":"Science"},{"issue":"6331","key":"1063_CR41","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1126\/science.aaf9011","volume":"355","author":"C Tomasetti","year":"2017","unstructured":"Tomasetti C, Li L, Vogelstein B. Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science. 2017;355(6331):1330\u20134.","journal-title":"Science"},{"issue":"2","key":"1063_CR42","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/ng1941","volume":"39","author":"M Widschwendter","year":"2007","unstructured":"Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, et al. Epigenetic stem cell signature in cancer. Nat Genet. 2007;39(2):157\u20138.","journal-title":"Nat Genet"},{"issue":"4","key":"1063_CR43","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1101\/gr.103606.109","volume":"20","author":"AE Teschendorff","year":"2010","unstructured":"Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Weisenberger DJ, Shen H, et al. Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res. 2010;20(4):440\u20136.","journal-title":"Genome Res"},{"issue":"7","key":"1063_CR44","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2217\/epi-2018-0037","volume":"10","author":"SC Zheng","year":"2018","unstructured":"Zheng SC, Webster AP, Dong D, Feber A, Graham DG, Sullivan R, et al. A novel cell-type deconvolution algorithm reveals substantial contamination by immune cells in saliva, buccal and cervix. Epigenomics. 2018;10(7):925\u201340.","journal-title":"Epigenomics"},{"issue":"8","key":"1063_CR45","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/j.celrep.2016.10.058","volume":"17","author":"D Pellacani","year":"2016","unstructured":"Pellacani D, Bilenky M, Kannan N, Heravi-Moussavi A, Knapp D, Gakkhar S, et al. Analysis of normal human mammary epigenomes reveals cell-specific active enhancer states and associated transcription factor networks. Cell Rep. 2016;17(8):2060\u201374.","journal-title":"Cell Rep"},{"issue":"9","key":"1063_CR46","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1093\/humrep\/den228","volume":"23","author":"M Engman","year":"2008","unstructured":"Engman M, Skoog L, Soderqvist G, Gemzell-Danielsson K. The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology. Hum Reprod. 2008;23(9):2072\u20139.","journal-title":"Hum Reprod"},{"key":"1063_CR47","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10549-021-06503-1","volume":"192","author":"CL Westhoff","year":"2022","unstructured":"Westhoff CL, Guo H, Wang Z, Hibshoosh H, Polaneczky M, Pike MC, et al. The progesterone-receptor modulator, ulipristal acetate, drastically lowers breast cell proliferation. Breast Cancer Res Treat. 2022;192:321\u20139.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"1063_CR48","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1001\/jamaoncol.2015.1053","volume":"1","author":"AE Teschendorff","year":"2015","unstructured":"Teschendorff AE, Yang Z, Wong A, Pipinikas CP, Jiao Y, Jones A, et al. Correlation of Smoking-Associated DNA Methylation Changes in Buccal Cells With DNA Methylation Changes in Epithelial Cancer. JAMA Oncol. 2015;1(4):476\u201385.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1063_CR49","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.celrep.2019.05.109","volume":"28","author":"JJ Salk","year":"2019","unstructured":"Salk JJ, Loubet-Senear K, Maritschnegg E, Valentine CC, Williams LN, Higgins JE, et al. Ultra-Sensitive TP53 sequencing for cancer detection reveals progressive clonal selection in normal tissue over a century of human lifespan. Cell Rep. 2019;28(1):132\u201344 e133.","journal-title":"Cell Rep"},{"issue":"7805","key":"1063_CR50","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41586-020-2214-z","volume":"580","author":"L Moore","year":"2020","unstructured":"Moore L, Leongamornlert D, Coorens THH, Sanders MA, Ellis P, Dentro SC, et al. The mutational landscape of normal human endometrial epithelium. Nature. 2020;580(7805):640\u20136.","journal-title":"Nature"},{"issue":"6417","key":"1063_CR51","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1126\/science.aau3879","volume":"362","author":"I Martincorena","year":"2018","unstructured":"Martincorena I, Fowler JC, Wabik A, Lawson ARJ, Abascal F, Hall MWJ, et al. Somatic mutant clones colonize the human esophagus with age. Science. 2018;362(6417):911\u20137.","journal-title":"Science"},{"issue":"7779","key":"1063_CR52","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41586-019-1672-7","volume":"574","author":"H Lee-Six","year":"2019","unstructured":"Lee-Six H, Olafsson S, Ellis P, Osborne RJ, Sanders MA, Moore L, et al. The landscape of somatic mutation in normal colorectal epithelial cells. Nature. 2019;574(7779):532\u20137.","journal-title":"Nature"},{"issue":"8","key":"1063_CR53","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1158\/0008-5472.CAN-21-3607","volume":"82","author":"J Matas","year":"2022","unstructured":"Matas J, Kohrn B, Fredrickson J, Carter K, Yu M, Wang T, et al. Colorectal cancer is associated with the presence of cancer driver mutations in normal colon. Cancer Res. 2022;82(8):1492\u2013502.","journal-title":"Cancer Res"},{"key":"1063_CR54","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/em.22409","volume":"61","author":"KL Harris","year":"2020","unstructured":"Harris KL, Walia V, Gong B, McKim KL, Myers MB, Xu J, et al. Quantification of cancer driver mutations in human breast and lung DNA using targeted, error-corrected CarcSeq. Environ Mol Mutagen. 2020;61:872\u201389.","journal-title":"Environ Mol Mutagen"},{"issue":"5","key":"1063_CR55","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrg.2017.117","volume":"19","author":"JJ Salk","year":"2018","unstructured":"Salk JJ, Schmitt MW, Loeb LA. Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat Rev Genet. 2018;19(5):269\u201385.","journal-title":"Nat Rev Genet"},{"issue":"8","key":"1063_CR56","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/nm.2000","volume":"15","author":"E Lim","year":"2009","unstructured":"Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med. 2009;15(8):907\u201313.","journal-title":"Nat Med"},{"issue":"9","key":"1063_CR57","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/jnci\/djr079","volume":"103","author":"J Cuzick","year":"2011","unstructured":"Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, et al. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst. 2011;103(9):744\u201352.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"1063_CR58","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756\u201365.","journal-title":"N Engl J Med"},{"issue":"3","key":"1063_CR59","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","volume":"20","author":"M Gnant","year":"2019","unstructured":"Gnant M, Pfeiler G, Steger GG, Egle D, Greil R, Fitzal F, et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(3):339\u201351.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1063_CR60","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.fertnstert.2011.08.021","volume":"96","author":"P Bouchard","year":"2011","unstructured":"Bouchard P, Chabbert-Buffet N, Fauser BC. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil Steril. 2011;96(5):1175\u201389.","journal-title":"Fertil Steril"},{"issue":"23","key":"1063_CR61","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1056\/NEJMe1604462","volume":"374","author":"MF Greene","year":"2016","unstructured":"Greene MF, Drazen JM. A New Label for Mifepristone. N Engl J Med. 2016;374(23):2281\u20132.","journal-title":"N Engl J Med"},{"issue":"7","key":"1063_CR62","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMp1908305","volume":"381","author":"JE Henney","year":"2019","unstructured":"Henney JE, Gayle HD. Time to Reevaluate U.S. Mifepristone Restrictions. N Engl J Med. 2019;381(7):597\u20138.","journal-title":"N Engl J Med"},{"key":"1063_CR63","first-page":"CD001324","volume":"1","author":"J Shen","year":"2019","unstructured":"Shen J, Che Y, Showell E, Chen K, Cheng L. Interventions for emergency contraception. Cochrane Database Syst Rev. 2019;1:CD001324.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"1063_CR64","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ajog.2017.12.206","volume":"218","author":"SS Singh","year":"2018","unstructured":"Singh SS, Belland L, Leyland N, von Riedemann S, Murji A. The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids. Am J Obstet Gynecol. 2018;218(6):563\u201372 e561.","journal-title":"Am J Obstet Gynecol"},{"key":"1063_CR65","first-page":"CD009881","volume":"7","author":"J Fu","year":"2017","unstructured":"Fu J, Song H, Zhou M, Zhu H, Wang Y, Chen H, et al. Progesterone receptor modulators for endometriosis. Cochrane Database Syst Rev. 2017;7:CD009881.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"1063_CR66","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/gme.0b013e3182176285","volume":"18","author":"C Bouchard","year":"2011","unstructured":"Bouchard C. Selective estrogen receptor modulators and their effects on hot flashes: a dilemma. Menopause. 2011;18(5):477\u20139.","journal-title":"Menopause"},{"key":"1063_CR67","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s40264-020-00975-8","volume":"43","author":"M Gatti","year":"2020","unstructured":"Gatti M, Poluzzi E, De Ponti F, Raschi E. Liver injury with ulipristal acetate: exploring the underlying pharmacological basis. Drug Saf. 2020;43:1277\u201385.","journal-title":"Drug Saf"},{"key":"1063_CR68","volume-title":"Breast tissue methylation analysis. Study ID EGAS00001005070, European Genome-phenome Archive","author":"K Gemzell-Danielsson","year":"2022","unstructured":"Gemzell-Danielsson K, Widschwendter M: Breast tissue methylation analysis. Study ID EGAS00001005070, European Genome-phenome Archive 2022, https:\/\/ega-archive.org\/studies\/EGAS00001005070"},{"key":"1063_CR69","series-title":"Series GSE69914, NCBI Gene Expression Omnibus","volume-title":"Genome wide DNA methylation profiling of normal breast, normal adjacent and breast cancer tissue","author":"A Teschendorff","year":"2022","unstructured":"Teschendorff A, Widschwendter M: Genome wide DNA methylation profiling of normal breast, normal adjacent and breast cancer tissue. Series GSE69914, NCBI Gene Expression Omnibus 2022, https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE69914"},{"key":"1063_CR70","series-title":"Series GSE201724, NCBI Gene Expression Omnibus","volume-title":"A pilot prevention study of the effects of the anti- progestin Ulipristal Acetate (UA) on surrogate markers of breast cancer risk","author":"B Sim\u00f5es","year":"2022","unstructured":"Sim\u00f5es B, Howell, M: A pilot prevention study of the effects of the anti- progestin Ulipristal Acetate (UA) on surrogate markers of breast cancer risk. Series GSE201724, NCBI Gene Expression Omnibus 2022, https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE201724"},{"key":"1063_CR71","series-title":"Series GSE157126, NCBI Gene Expression Omnibus","volume-title":"Targeting progesterone to reduce epigenetic breast cancer risk surrogates in humans","author":"NR Bogavarappu","year":"2022","unstructured":"Bogavarappu, NR, Gemzell-Danielsson K: Targeting progesterone to reduce epigenetic breast cancer risk surrogates in humans. Series GSE157126, NCBI Gene Expression Omnibus 2022, https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE157126"}],"updated-by":[{"DOI":"10.1186\/s13073-022-01086-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000}}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-022-01063-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-022-01063-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-022-01063-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T17:07:26Z","timestamp":1666458446000},"score":1,"resource":{"primary":{"URL":"https:\/\/genomemedicine.biomedcentral.com\/articles\/10.1186\/s13073-022-01063-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,15]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1063"],"URL":"https:\/\/doi.org\/10.1186\/s13073-022-01063-5","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13073-022-01086-y","asserted-by":"object"}]},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,15]]},"assertion":[{"value":"11 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13073-022-01086-y","URL":"https:\/\/doi.org\/10.1186\/s13073-022-01086-y","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Clinical Trials 1\u20132 <i>(\u2018Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control \u2013 a randomized controlled trial\u2019<\/i> and <i>\u2018The effect of a progesterone receptor modulator on breast tissue in women with BRCA1 and 2 mutations\u2019<\/i>) were approved by the regional ethical review board at Karolinska Institutet permit 2009\/144-31\/4 and the regional ethical review board at Karolinska Institutet permit 2012\/729 31\/1; Clinical Trial 3 (<i>\u2018A pilot prevention study of the effects of the anti- progestin Ulipristal Acetate (UA) on surrogate markers of breast cancer risk\u2019<\/i>) was approved by Greater Manchester \u2013 South, Research Ethics Committee (REC number 15\/NW\/0478). Clinical Trials 1\u20133 conformed to the principles of the Helsinki Declaration. Informed consent was obtained from all participants in Clinical Trials 1\u20133 to cover all genomic analyses carried out in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RAR owns equity and serves as a scientific consultant to TwinStrand Biosciences Inc. UCLB (UCL's commercialisation company) has filed a patent on some aspects described in the paper \u2013 MW is named as inventor on this patent. JEB, CH and MW are shareholders of Sola Diagnostics GmbH, which holds an exclusive licence to the intellectual property described in this patent file. The remaining authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}